Aspirin and asthma: barking up the right tree?

Andrew A Clayton, Douglas L Forrester, Alan J Knox

According to World Health Organization estimates, 300 million people worldwide suffer from asthma. It is the most common chronic condition in childhood and continues to impose a high burden of morbidity and mortality in adulthood; over 250 000 people are thought to have died from asthma in 2005. In the UK 5.2 million children are currently receiving treatment for asthma.

There has been an apparent increase in incidence over recent years, at least in children and adolescents. Data in adults are more sparse but suggest that incidence increases slightly with age, albeit to a level much lower than that in children. The aetiology of asthma at all ages is still not fully understood although environmental allergens, immunological and genetic factors are all known to contribute. In this issue of Thorax Kurth et al report interesting post hoc data from the Women’s Health Study which suggest that assignment of 100 mg aspirin on alternate days reduces the relative risk of newly reported diagnosis of asthma in otherwise healthy adult women (see page 514).

The first descriptions of aspirin-like medication come from the time of Hippocrates when the bark of the white willow was used as an antipyretic agent. In the 1700s its use is again described to treat “ague” (fever). The active compound was extracted and purified during the 1800s. Most physicians associate aspirin with its ability to precipitate or worsen asthma symptoms. Aspirin-sensitivity asthma is in fact a distinct clinical syndrome. Bayer released aspirin onto the market in 1899 as an analgesic and antipyretic agent.34 It became clear soon after this that aspirin or other non-steroidal anti-inflammatory agents are able to precipitate or worsen asthma symptoms.6,7

References

1. Text continues...
Two recent large studies have suggested that aspirin use can reduce the risk of adult-onset asthma. Other studies have shown that some individuals with asthma improve after challenge with aspirin or non-steroidal anti-inflammatory drugs (NSAIDs). The Women’s Health Study was designed to determine the effect of aspirin and vitamin E on cardiovascular risk. Kurth and colleagues have performed post hoc analysis on the data to assess the effects of aspirin on new diagnoses of asthma. The women taking part were all over 45 years of age and mainly Caucasian, with no history of major previous illnesses. A total of 39,876 women entered the study; previous aspirin or NSAID use was not documented but was assumed to be equal in both groups due to the sample size. Women reporting a diagnosis of asthma during the trial. Clearly, this may be an important confounding factor.

Of potentially greater concern is the observation that women randomised to aspirin had a significantly increased risk of gastrointestinal bleeding requiring blood transfusion (relative risk 1.40; 95% confidence interval 1.07 to 1.83). It is debatable whether such a risk is acceptable in order to achieve the reduction in asthma risk.

Despite these limitations, the observations made by Kurth et al and others seem tenable. It is clear that further studies are needed specifically to test the hypothesis that aspirin can reduce the risk of developing adult-onset asthma.

Competing interests: None.

REFERENCES